Pfizer, Inc. (PFE) Stake Lessened by Boyd Watterson Asset Management LLC OH

Boyd Watterson Asset Management LLC OH reduced its stake in shares of Pfizer, Inc. (NYSE:PFE) by 5.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,932 shares of the biopharmaceutical company’s stock after selling 5,323 shares during the quarter. Pfizer makes up approximately 1.5% of Boyd Watterson Asset Management LLC OH’s investment portfolio, making the stock its 15th largest position. Boyd Watterson Asset Management LLC OH’s holdings in Pfizer were worth $2,853,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Asset Planning Services Ltd. boosted its stake in shares of Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 137 shares during the period. Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer during the first quarter valued at $121,000. Patten Group Inc. boosted its stake in shares of Pfizer by 5.1% during the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 252 shares during the period. Acropolis Investment Management LLC boosted its stake in shares of Pfizer by 6.7% during the second quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 352 shares during the period. Finally, Kimelman & Baird LLC purchased a new stake in shares of Pfizer during the first quarter valued at $203,000. 68.99% of the stock is owned by hedge funds and other institutional investors.

In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock valued at $15,813,961 over the last 90 days. 0.06% of the stock is currently owned by insiders.

A number of brokerages have recently issued reports on PFE. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a research note on Tuesday, October 3rd. Berenberg Bank set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Finally, Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a research note on Wednesday, September 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $38.10.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thestockobserver.com/2017/10/13/pfizer-inc-pfe-stake-lessened-by-boyd-watterson-asset-management-llc-oh.html.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.64 earnings per share.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.52%. Pfizer’s dividend payout ratio is presently 94.12%.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply